NCT02909751View on ClinicalTrials.gov

Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 14, 2016

Primary Completion Date

January 21, 2019

Study Completion Date

January 21, 2019

Conditions
Breast Cancer
Interventions
DRUG

Epirubicin 90 mg/m2 iv

Max. 3 months

DRUG

Cyclophosphamide 600 mg/m2 iv

Max. 3 months

DRUG

Docetaxel 100 mg/m2 iv OR paclitaxel 80 mg/m2 iv

Max. 3 months

DRUG

Trastuzumab 8 mg/kg iv saturation, then 6 mg/kg iv (HER2 positive patients only)

Max. 3 months.

DRUG

Pertuzumab 840 mg iv saturation, then 420 mg iv (selected HER2 positive patients only)

Max. 3 months

DIETARY_SUPPLEMENT

Tocotrienol 300 mg x 3 daily

Max. 6 months

Trial Locations (1)

Unknown

Vejle hospital, Department of Oncology, Vejle

All Listed Sponsors
lead

Vejle Hospital

OTHER

NCT02909751 - Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer | Biotech Hunter | Biotech Hunter